314 related articles for article (PubMed ID: 36895553)
1. Self-assembled nanoparticles: A new platform for revolutionizing therapeutic cancer vaccines.
Shi T; Sun M; Lu C; Meng F
Front Immunol; 2023; 14():1125253. PubMed ID: 36895553
[TBL] [Abstract][Full Text] [Related]
2. Advances in Cancer Vaccine Research.
Liu N; Xiao X; Zhang Z; Mao C; Wan M; Shen J
ACS Biomater Sci Eng; 2023 Nov; 9(11):5999-6023. PubMed ID: 37921277
[TBL] [Abstract][Full Text] [Related]
3. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
Li WH; Su JY; Li YM
Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
[TBL] [Abstract][Full Text] [Related]
4. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
[TBL] [Abstract][Full Text] [Related]
5. Efficient co-delivery of neo-epitopes using dispersion-stable layered double hydroxide nanoparticles for enhanced melanoma immunotherapy.
Zhang LX; Xie XX; Liu DQ; Xu ZP; Liu RT
Biomaterials; 2018 Aug; 174():54-66. PubMed ID: 29778982
[TBL] [Abstract][Full Text] [Related]
6. Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor.
Fontana F; Fusciello M; Groeneveldt C; Capasso C; Chiaro J; Feola S; Liu Z; Mäkilä EM; Salonen JJ; Hirvonen JT; Cerullo V; Santos HA
ACS Nano; 2019 Jun; 13(6):6477-6490. PubMed ID: 31100004
[TBL] [Abstract][Full Text] [Related]
7. Preclinical models and technologies to advance nanovaccine development.
Peres C; Matos AI; Moura LIF; Acúrcio RC; Carreira B; Pozzi S; Vaskovich-Koubi D; Kleiner R; Satchi-Fainaro R; Florindo HF
Adv Drug Deliv Rev; 2021 May; 172():148-182. PubMed ID: 33711401
[TBL] [Abstract][Full Text] [Related]
8. Solid-in-Oil Peptide Nanocarriers for Transcutaneous Cancer Vaccine Delivery against Melanoma.
Wakabayashi R; Sakuragi M; Kozaka S; Tahara Y; Kamiya N; Goto M
Mol Pharm; 2018 Mar; 15(3):955-961. PubMed ID: 29397746
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic vaccination with tumor cells that engage CD137.
Hellstrom KE; Hellstrom I
J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523
[TBL] [Abstract][Full Text] [Related]
10. Impact of dose, route, and composition on the immunogenicity of immune polyelectrolyte multilayers delivered on gold templates.
Zhang P; Andorko JI; Jewell CM
Biotechnol Bioeng; 2017 Feb; 114(2):423-431. PubMed ID: 27567213
[TBL] [Abstract][Full Text] [Related]
11. Combining DNA Vaccine and AIM2 in H1 Nanoparticles Exert Anti-Renal Carcinoma Effects via Enhancing Tumor-Specific Multi-functional CD8
Chai D; Shan H; Wang G; Zhang Q; Li H; Fang L; Song J; Liu N; Zhang Q; Yao H; Zheng J
Mol Cancer Ther; 2019 Feb; 18(2):323-334. PubMed ID: 30401695
[TBL] [Abstract][Full Text] [Related]
12.
Yazdani M; Jaafari MR; Verdi J; Alani B; Noureddini M; Badiee A
Immunotherapy; 2020 Apr; 12(5):333-349. PubMed ID: 32212934
[TBL] [Abstract][Full Text] [Related]
13. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis.
Xu Z; Ramishetti S; Tseng YC; Guo S; Wang Y; Huang L
J Control Release; 2013 Nov; 172(1):259-265. PubMed ID: 24004885
[TBL] [Abstract][Full Text] [Related]
14. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.
De Pas T; Giovannini M; Rescigno M; Catania C; Toffalorio F; Spitaleri G; Delmonte A; Barberis M; Spaggiari L; Solli P; Veronesi G; De Braud F
Crit Rev Oncol Hematol; 2012 Sep; 83(3):432-43. PubMed ID: 22366114
[TBL] [Abstract][Full Text] [Related]
15. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a self-assembling and self-adjuvant lipopeptide as a saccharide-free peptide vaccine targeting EGFRvIII positive cutaneous melanoma.
Chen Y; Yuan F; Jiang X; Lv Q; Luo N; Gong C; Wang C; Yang L; He G
Biomater Sci; 2018 May; 6(5):1120-1128. PubMed ID: 29528348
[TBL] [Abstract][Full Text] [Related]
17. A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy.
Duperret EK; Liu S; Paik M; Trautz A; Stoltz R; Liu X; Ze K; Perales-Puchalt A; Reed C; Yan J; Xu X; Weiner DB
Clin Cancer Res; 2018 Dec; 24(23):6015-6027. PubMed ID: 30262507
[TBL] [Abstract][Full Text] [Related]
18. Current state of vaccine therapies in non-small-cell lung cancer.
Romero P
Clin Lung Cancer; 2008 Feb; 9 Suppl 1():S28-36. PubMed ID: 18540532
[TBL] [Abstract][Full Text] [Related]
19. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
20. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM
J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
